Section Arrow
RNA.NASDAQ
- Avidity Biosciences
Quotes are at least 15-min delayed:2026/01/05 07:20 EST
Pre Market
Last
 --
-- (--)
Bid
72.01
Ask
72.15
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 72.1
-0.03 (-0.04%)
Day High 
72.16 
Prev. Close
72.13 
1-M High
72.61 
Volume 
2.81M 
Bid
72.01
Ask
72.15
Day Low
72 
Open
72.15 
1-M Low
71.12 
Market Cap 
10.86B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 72.14 
20-SMA 71.87 
50-SMA 69.29 
52-W High 72.61 
52-W Low 21.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.19/-2.78
Enterprise Value
10.87B
Balance Sheet
Book Value Per Share
12.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
10.90M
Operating Revenue Per Share
0.07
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
Pre Market 0.6991 +0.0391 +5.92%
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
Pre Market 0.5413 +0.0309 +6.05%
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
Pre Market 4.71 +0.36 +8.28%
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
Pre Market 0.1438 +0.0069 +5.04%
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Pre Market 4.28 +0.08 +1.90%
Industry overview quotes are at least 15 minutes delayed
Business Description
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.